Overview
NICE is unable to make a recommendation about the use in the NHS of denosumab for preventing skeletal-related events in multiple myeloma because no evidence submission was received from Amgen.
Last reviewed: 5 December 2018
Next review: We will review this decision if the company decides to make a submission.